Healthcare provider profile · identity verified

Megan Sumigray, M.D.

Family Practice · AMSTERDAM, NY · NPI 1437509478

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	441	147
Levothyroxine Sodium	Levothyroxine Sodium	317	105
Omeprazole	Omeprazole	277	100
Gabapentin	Gabapentin	220	60
Albuterol Sulfate Hfa	Albuterol Sulfate	215	69
Lisinopril	Lisinopril	186	75
Amlodipine Besylate	Amlodipine Besylate	178	64
Losartan Potassium	Losartan Potassium	176	62
Simvastatin	Simvastatin	152	62
Famotidine	Famotidine	131	50
Furosemide	Furosemide	129	44
Hydrochlorothiazide	Hydrochlorothiazide	126	46
Metformin Hcl	Metformin Hcl	120	45
Pantoprazole Sodium	Pantoprazole Sodium	107	33
Metoprolol Succinate	Metoprolol Succinate	103	42
Montelukast Sodium	Montelukast Sodium	102	33
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	89	20
Metoprolol Tartrate	Metoprolol Tartrate	89	32
Trazodone Hcl	Trazodone Hcl	86	33
Ozempic	Semaglutide	84	22
Rosuvastatin Calcium	Rosuvastatin Calcium	81	32
Potassium Chloride	Potassium Chloride	73	24
Synthroid	Levothyroxine Sodium	73	22
Eliquis	Apixaban	67	21
Tamsulosin Hcl	Tamsulosin Hcl	66	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	65	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	24
Ibuprofen	Ibuprofen	62	18
Sertraline Hcl	Sertraline Hcl	62	22
Tizanidine Hcl	Tizanidine Hcl	62	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	59	26
Prednisone	Prednisone	58	35
Citalopram Hbr	Citalopram Hydrobromide	57	20
Pravastatin Sodium	Pravastatin Sodium	57	20
Duloxetine Hcl	Duloxetine Hcl	56	17
Jardiance	Empagliflozin	55	18
Zolpidem Tartrate	Zolpidem Tartrate	54	12
Metformin Hcl Er	Metformin Hcl	52	21
Buspirone Hcl	Buspirone Hcl	51	18
Fluticasone Propionate	Fluticasone Propionate	47	22
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	46	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	13
Allopurinol	Allopurinol	41	11
Alprazolam	Alprazolam	41	18
Fluoxetine Hcl	Fluoxetine Hcl	40	12
Celecoxib	Celecoxib	39	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	39	suppressed
Glipizide	Glipizide	38	suppressed
Paroxetine Hcl	Paroxetine Hcl	38	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Meloxicam	Meloxicam	37	16
Pregabalin	Pregabalin	37	suppressed
Bupropion Xl	Bupropion Hcl	36	12
Clonazepam	Clonazepam	34	suppressed
Spironolactone	Spironolactone	34	12
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Ventolin Hfa	Albuterol Sulfate	33	suppressed
Tramadol Hcl	Tramadol Hcl	32	12
Trulicity	Dulaglutide	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	13
Fenofibrate	Fenofibrate	28	12
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	25
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	suppressed
Ramipril	Ramipril	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Lansoprazole	Lansoprazole	25	suppressed
Valsartan	Valsartan	25	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Baclofen	Baclofen	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Ondansetron Odt	Ondansetron	23	12
Torsemide	Torsemide	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	16
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Atenolol	Atenolol	21	suppressed
Nystatin	Nystatin	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Azithromycin	Azithromycin	20	17
Linzess	Linaclotide	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	suppressed
Novolog Flexpen	Insulin Aspart	20	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	18	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	15
Finasteride	Finasteride	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Amoxicillin	Amoxicillin	15	suppressed
Breyna	Budesonide/Formoterol Fumarate	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Carvedilol	Carvedilol	15	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Sucralfate	Sucralfate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Ibu	Ibuprofen	12	suppressed
Topiramate	Topiramate	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Wegovy	Semaglutide	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error